menu
    • menu
    [{"orgOrder":0,"company":"Syndesi Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$130.0 million","newsHeadline":"AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"SDI-118","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Syndesi Therapeutics","amount2":1,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1,"dosageForm":"Capsule","sponsorNew":"Syndesi Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Syndesi Th.."}]

    Find Clinical Drug Pipeline Developments & Deals by Syndesi Therapeutics

    Menu

    Syndesi Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syndesi Therapeutics

                            Belgium arrow
                            26th North American ISSX
                            Not Confirmed

                            Syndesi Therapeutics

                            Belgium arrow
                            26th North American ISSX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SDI-118

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : AbbVie Inc

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

                            Details : AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluati...

                            Product Name : SDI-118

                            Product Type : Small molecule

                            Upfront Cash : $130.0 million

                            March 01, 2022

                            Lead Product(s) : SDI-118

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Partner/Sponsor/Collaborator : AbbVie Inc

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth